Sedana Medical AB (publ)
STO:SEDANA
Net Margin
Sedana Medical AB (publ)
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SE |
|
Sedana Medical AB (publ)
STO:SEDANA
|
906m SEK |
-6%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
219.3B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
181.3B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
150.8B USD |
11%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140.3B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
113.2B USD |
13%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
66.1B USD |
8%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
56.6B EUR |
9%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
41.8B USD |
77%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
293.4B CNY |
33%
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
37B USD |
10%
|
Sedana Medical AB (publ)
Glance View
Sedana Medical AB is a medical technology company, which engages in the development, manufacture, and sale of medical devices and drug development for future projects around AnaConDa. The company is headquartered in Danderyd, Stockholm. The company went IPO on 2017-06-21. The company develops, markets and sales medical devices and conducts drug development for future projects around AnaConDa technology. The AnaConDa technology delivery enables of volatile anaesthetics to invasively ventilated patients. The products portfolio comprises disposable medical devices AnaConDa for administration of volatile anaesthetics, AnaConDa syringes, FlurAbsorb charcoal filters for removing halogenated hydrocarbon anaesthetic gases, different lines and connectors which can be used to connect the FlurAbsorb filter, adaptors, among others. The Company’s main shareholders are board members, Linc AB and Magiola Consulting AB.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Sedana Medical AB (publ)'s most recent financial statements, the company has Net Margin of -6%.
You don't have any saved screeners yet